T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Pathward Financial
CASH
$1.79B
| $220K | ﹤0.01% |
+6,652
| New | +$239K |
|
2502
Frontline
FRO
$9.02B
| $220K | ﹤0.01% |
20,105
+8,087
| +67% | +$88.6K |
|
|
ME
2503
DELISTED
23andMe Holding Co
ME
| $220K | ﹤0.01% |
3,835
+1,215
| +46% | +$79.5K |
|
2504
Dutch Bros
BROS
$8.93B
| $219K | ﹤0.01% |
7,000
-1,017,255
| -99% | -$38.3M |
|
2505
Core & Main
CNM
$8.64B
| $218K | ﹤0.01% |
+9,581
| New | +$224K |
|
2506
Customers Bancorp
CUBI
$2.82B
| $217K | ﹤0.01% |
7,337
-3,446
| -32% | -$122K |
|
|
ORC
2507
Orchid Island Capital
ORC
$1.32B
| $216K | ﹤0.01% |
26,273
+2,125
| +9% | +$29.5K |
|
2508
uniQure
QURE
$3.26B
| $216K | ﹤0.01% |
11,500
-464,417
| -98% | -$9.76M |
|
2509
Anika Therapeutics
ANIK
$283M
| $215K | ﹤0.01% |
+8,998
| New | +$207K |
|
2510
Cardlytics
CDLX
$25.1M
| $214K | ﹤0.01% |
2,275
+517
| +29% | +$73.6K |
|
2511
Invesco Mortgage Capital
IVR
$805M
| $214K | ﹤0.01% |
19,219
+2,055
| +12% | +$32K |
|
2512
Universal Technical Institute
UTI
$1.42B
| $214K | ﹤0.01% |
39,207
+2,317
| +6% | +$16.2K |
|
2513
Lemonade
LMND
$4.1B
| $213K | ﹤0.01% |
+10,025
| New | +$228K |
|
2514
PMV Pharmaceuticals
PMVP
$65.1M
| $213K | ﹤0.01% |
17,864
+2,251
| +14% | +$32.5K |
|
2515
ZipRecruiter
ZIP
$388M
| $213K | ﹤0.01% |
+12,886
| New | +$225K |
|
|
CTIC
2516
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $210K | ﹤0.01% |
35,939
+6,900
| +24% | +$43K |
|
2517
Driven Brands
DRVN
$2.12B
| $208K | ﹤0.01% |
+7,425
| New | +$229K |
|
2518
Ecovyst
ECVT
$1.1B
| $208K | ﹤0.01% |
24,555
+5,969
| +32% | +$56.8K |
|
2519
IDT Corp
IDT
$1.67B
| $208K | ﹤0.01% |
+8,338
| New | +$214K |
|
2520
Vuzix
VUZI
$220M
| $208K | ﹤0.01% |
35,907
+6,859
| +24% | +$52.9K |
|
|
MODN
2521
DELISTED
MODEL N, INC.
MODN
| $208K | ﹤0.01% |
+6,064
| New | +$175K |
|
2522
Hayward Holdings
HAYW
$3.24B
| $207K | ﹤0.01% |
23,262
-647,284
| -97% | -$7.61M |
|
2523
Inovio Pharmaceuticals
INO
$93M
| $207K | ﹤0.01% |
9,956
-751
| -7% | -$19.2K |
|
|
KZR
2524
DELISTED
Kezar Life Sciences
KZR
| $207K | ﹤0.01% |
2,396
+862
| +56% | +$83.7K |
|
2525
Forestar Group
FOR
$1.51B
| $206K | ﹤0.01% |
18,397
+2,942
| +19% | +$39K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.